Aquestive Therapeutics, Inc. provided preliminary revenue guidance for the fourth quarter and full year ended December 31, 2019 and revenue guidance for the full year 2020. For the quarter, the company expects its preliminary unaudited total revenues are anticipated to be approximately $16 million and approximately $52 million for the full year ended December 31, 2019. 2019 total revenue performance was driven by the continued strength throughout the year, prior to Indivior’s announcement of the discontinuance of its authorized generic product, of Suboxone® and Indivior’s authorized generic product. For the full year 2020, the company expects total revenues of approximately $35 million to $45 million.